phrykt

Arvinas, Inc. (ARVN): who owns it and who trades it

As of Nov 16, 2026, ARVN insiders reported 21 open-market sales worth $1.3M and 1 purchase worth $268K in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was John G Houston (Director), with $466K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Arvinas

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ARVN

198 funds and institutions reported ARVN shares worth $478M at the end of Q2 2026, about 88% of the company. The largest holder is BlackRock, Inc. with 11.8%.

Funds and institutions (13F) 88%Everyone else 12%

10 largest owners, by share of the company

BlackRock, Inc.11.8%
Vanguard Portfolio Management LLC6.4%
D. E. Shaw & Co., Inc.5.4%
Pfizer Inc5.4%
Armistice Capital, LLC4.3%
Vanguard Capital Management LLC4.2%
Two Sigma Investments, LP4.0%
State Street Corp3.4%
Geode Capital Management, LLC2.6%
Qube Research & Technologies Ltd2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.7.61M11.79%$63.2M+12%
Vanguard Portfolio Management LLC4.12M6.39%$34.3M+6%
D. E. Shaw & Co., Inc.3.50M5.42%$29M-4%
Pfizer Inc3.46M5.36%$27.7MNo change
Armistice Capital, LLC2.80M4.33%$23.2M+41%
Vanguard Capital Management LLC2.71M4.21%$22.6M+1%
Two Sigma Investments, LP2.57M3.99%$21.4M+40%
State Street Corp2.20M3.40%$18.3M+20%
Geode Capital Management, LLC1.67M2.58%$13.9M+7%
Qube Research & Technologies Ltd1.59M2.47%$13.2M+33%
Jacobs Levy Equity Management, Inc1.41M2.19%$11.7M-2%
Federated Hermes, Inc.1.36M2.10%$11.3M+19%
Nextech Invest Ltd.1.12M1.74%$17.1M+108%
Acadian Asset Management LLC848,3821.31%$7M-11%
Hillsdale Investment Management Inc.750,9001.16%$6.2M–
T. Rowe Price Associates728,1471.13%$6.1M+70%
TCG Crossover Management, LLC707,0981.10%$5.9M-70%
Dimensional Fund Advisors LP654,9091.02%$5.4M+35%
Goldman Sachs Group Inc640,8110.99%$5.3M-15%
Citadel Advisors LLC620,9730.96%$5.2M-47%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ARVN insiders reported $268K of open-market purchases and $1.3M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$268K
1 trades, 1 people
Sales, 12 months
$1.3M
21 trades, 6 people
Sales under a 10b5-1 plan
5%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 9, 2026

Purchases and sales by month

$817K$817KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026David K LoomisVice presidentSale plan232$6.36$1.5KForm 4
Jun 24, 2026Andrew SaikCFOSale plan5,696$8.16$46.5KForm 4
Jun 17, 2026Angela M CacaceChief Scientific OfficerSale plan2,576$7.60$19.6KForm 4
May 21, 2026Randy TeelCEOSale2,209$9.04$20KForm 4
May 11, 2026Andrew SaikCFOSale11,139$9.94$111KForm 4
May 11, 2026David K LoomisVice presidentSale1,919$9.94$19.1KForm 4
May 11, 2026Angela M CacaceChief Scientific OfficerSale9,657$9.94$96KForm 4
May 11, 2026Noah BerkowitzChief Medical OfficerSale11,108$9.94$110KForm 4
Mar 18, 2026Noah BerkowitzChief Medical OfficerSale6,435$11.10$71.4KForm 4
Mar 6, 2026Briggs MorrisonDirectorPurchase20,000$13.40$268KForm 4
Feb 27, 2026John G HoustonDirectorSale4,688$13.24$62.1KForm 4
Feb 27, 2026John G HoustonDirectorSale18,822$13.24$249KForm 4
Feb 27, 2026John G HoustonDirectorSale11,787$13.14$155KForm 4
Feb 23, 2026David K LoomisChief Accounting OfficerSale1,108$12.16$13.5KForm 4
Feb 23, 2026Angela M CacaceChief Scientific OfficerSale2,571$12.16$31.3KForm 4
Feb 23, 2026Angela M CacaceChief Scientific OfficerSale1,038$12.16$12.6KForm 4
Feb 23, 2026Randy TeelCEOSale3,748$12.16$45.6KForm 4
Feb 13, 2026Randy TeelCEOSale4,403$11.89$52.4KForm 4
Feb 13, 2026Andrew SaikCFOSale5,134$11.89$61KForm 4
Feb 13, 2026Angela M CacaceChief Scientific OfficerSale4,592$11.89$54.6KForm 4
Feb 13, 2026Noah BerkowitzChief Medical OfficerSale5,685$11.89$67.6KForm 4
Feb 13, 2026David K LoomisChief Accounting OfficerSale1,016$11.89$12.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John G HoustonDirector–$466KFeb 27, 2026
Briggs MorrisonDirector$268K–Mar 6, 2026
Noah BerkowitzChief Medical Officer–$249KMay 11, 2026
Andrew SaikChief Financial Officer–$218KJun 24, 2026
Angela M CacaceChief Scientific Officer–$214KJun 17, 2026
Randy TeelPresident and CEO, Director–$118KMay 21, 2026
David K LoomisChief Accounting Officer–$46.1KNov 9, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ARVN short interest

Moderate short interest. 8.8% of ARVN shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.75M ARVN shares were sold short, 8.8% of the shares outstanding, up 2.8% from the report before. At the average daily volume of 757,464 shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

8.78%May 15Oct 309.18%

Days to cover

7.6May 15Oct 308.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.75M8.78%+3%757,4647.6
Oct 15, 20265.59M8.55%+4%684,3788.2
Sep 30, 20265.39M8.24%+8%819,2176.6
Sep 15, 20264.99M7.63%+6%891,5835.6
Aug 31, 20264.71M7.21%+16%585,8018.0
Aug 14, 20264.05M6.20%+1%1.22M3.3
Jul 31, 20264.00M6.11%+0%574,2307.0
Jul 15, 20263.98M6.17%-7%601,2886.6
Jun 30, 20264.27M6.62%-5%930,3544.6
Jun 15, 20264.49M6.96%-5%775,0375.8
May 29, 20264.71M7.29%-7%800,1785.9
May 15, 20265.04M7.81%+14%1.15M4.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Arvinas company events

Arvinas filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 25, 2026VoteReported shareholder vote results. Filing
  4. Jun 22, 2026LeadershipArvinas, Inc., a Delaware corporation, and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026. Filing
  5. Jun 16, 2026AnnouncementAs previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation, and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc., entered into a license… Filing
  6. Jun 2, 2026AnnouncementFollowing a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. May 12, 2026AgreementArvinas, Inc., a Delaware corporation, and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc., entered into a license agreement with Rigel Pharmaceuticals, Inc. Filing
  9. May 1, 2026AnnouncementThe Company issued a press release announcing that the FDA has granted approval for VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of… Filing
  10. Mar 18, 2026AnnouncementThe Company issued a press release announcing positive Phase 1 clinical trial data for ARV-102, an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK, showing greater than 50% LRRK2 degradation in the CSF of patients with… Filing
  11. Feb 24, 2026ResultsReleased financial results. Filing
  12. Feb 12, 2026LeadershipJohn Houston, Ph.D., notified Arvinas, Inc. of his decision to resign as president, chief executive officer and chairperson of the Company’s board of directors, effective February 12, 2026. Filing
  13. Dec 8, 2025AnnouncementThe Company issued a press release announcing preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Arvinas financials

Famous investors that hold ARVN

4 of the 50 well-known investors we track reported holding ARVN in their latest 13F filing. The largest position is Ken Griffin's, worth $9.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.23M$9.5M0.0%+98%
Jim Simons · Renaissance TechnologiesQ3 2026577,616$4.5M0.0%+168%
Israel Englander · Millennium ManagementQ3 202684,699$655K0.0%-85%
Paul Tudor Jones · Tudor Investment CorpQ3 202629,470$228K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ARVN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026D. E. Shaw & Co., L.P.13G/A4.9%
Nov 16, 2026D. E. Shaw & Co., L.P.13G/A4.9%

Questions about Arvinas, Inc. (ARVN) stock

Who owns the most ARVN stock?

The largest reported owner of Arvinas, Inc. (ARVN) is BlackRock, Inc., with 11.8% of the company. In total, 198 funds and institutions reported holding ARVN at the end of Q2 2026, together about 88% of the shares. See the largest owners.

Are ARVN insiders buying or selling?

In the last 12 months, ARVN insiders reported 1 open-market purchase worth $268K and 21 sales worth $1.3M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in ARVN?

As of Oct 30, 2026, 5.75M ARVN shares were sold short, 8.8% of the shares outstanding, up 2.8% from the report before. At the average daily volume of 757,464 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Which famous investors hold ARVN?

4 of the 50 well-known investors we track reported ARVN in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $9.5M. See all holders.

Executive pay

Arvinas's chief executive was paid a total of $6.5M for the year ended Dec 31, 2025, down 49% from $12.7M the year before. In the last 12 months, Arvinas's executives and directors bought $268K of stock on the open market and sold $1.3M.

Chief executive, total pay$6.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.